BIO-106 is under clinical development by BiOneCure Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BIO-106’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BIO-106 is under development for the treatment of solid tumors including triple-negative breast cancer (TNBC), HR positive/HER2 metastatic breast cancer and non-small cell lung cancer (NSCLC). The therapeutic candidate is an antibody-drug conjugate (ADC) that targets cells expressing Trop-2. It is being developed based on the TAM payload technology.
BiOneCure Therapeutics overview
BiOneCure Therapeutics provides antibody-based therapeutics of cancer. BiOneCure Therapeutics is headquartered in Germantown, Maryland, the US.
For a complete picture of BIO-106’s drug-specific PTSR and LoA scores, buy the report here.